V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a

EMBO Molecular Medicine

Volumn 2, Issue 11, 2010, Pages 458-471

  Carragher, Linda A S ^a   Snell, Kimberley R ^a   Giblett, Susan M ^a   Aldridge, Victoria S S ^a   Patel, Bipin ^a   Cook, Simon J ^b   Winton, Doug J ^c   Marais, Richard ^d   Pritchard, Catrin A ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b BABRAHAM INSTITUTE   (United Kingdom)

^c CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Braf; intestine; mouse model; senescence; serrated colorectal cancer

Indexed keywords

B RAF KINASE; BETA CATENIN; BETA GALACTOSIDASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P16; CDKN2A PROTEIN, MOUSE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DISEASE ASSOCIATION; DOWN REGULATION; EXON; GENE EXPRESSION; GENE MUTATION; METHYLATION; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENESCENCE; SMALL INTESTINE; TUMOR GROWTH; UPREGULATION; AGING; ANIMAL; BIOSYNTHESIS; CELL NUCLEUS; CHEMISTRY; COLORECTAL TUMOR; DNA METHYLATION; GASTROINTESTINAL TRACT; GENE EXPRESSION PROFILING; GENETICS; HYPERPLASIA; METABOLISM; MISSENSE MUTATION; PATHOLOGY; PATHOPHYSIOLOGY;

AGING; AMINO ACID SUBSTITUTION; ANIMALS; BETA CATENIN; CELL NUCLEUS; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; GASTROINTESTINAL TRACT; GENE EXPRESSION PROFILING; GLYCOGEN SYNTHASE KINASE 3; HYPERPLASIA; MICE; MUTATION, MISSENSE; PROTO-ONCOGENE PROTEINS B-RAF; UP-REGULATION;

EID: 78649307591     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201000099     Document Type: Article

References (51)

1. Agger K, Cloos PA, Rudkjaer L, Williams K, Andersen G, Christensen J, Helin K, (2009) The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev 23: 1171 - 1176
2. Aitken J, Welch J, Duffy D, Milligan A, Green A, Martin N, Hayward N, (1999) CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 91: 446 - 452
3. Amini Nik S, Hohenstein P, Jadidizadeh A, Van Dam K, Bastidas A, Berry RL, Patek CE, Van der Schueren B, Cassiman JJ, Tejpar S, (2005) Upregulation of Wilms' tumor gene 1 (WT1) in desmoid tumors. Int J Cancer 114: 202 - 208
4. Barradas M, Anderton E, Acosta JC, Li S, Banito A, Rodriguez-Niedenfuhr M, Maertens G, Banck M, Zhou MM, Walsh MJ, et al, (2009) Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev 23: 1177 - 1182
5. Beach R, Chan AO, Wu TT, White JA, Morris JS, Lunagomez S, Broaddus RR, Issa JP, Hamilton SR, Rashid A, (2005) BRAF mutations in aberrant crypt foci and hyperplastic polyposis. Am J Pathol 166: 1069 - 1075
6. Chan TL, Zhao W, Leung SY, Yuen ST, (2003) BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res 63: 4878 - 4881
7. Collado M, Serrano M, (2006) The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 6: 472 - 476
8. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguria A, Zaballos A, Flores JM, Barbacid M, et al, (2005) Tumour biology: senescence in premalignant tumours. Nature 436: 642
9. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M, (2007) A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 21: 379 - 384
10. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al, (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949 - 954
11. Deng G, Bell I, Crawley S, Gum J, Terdiman JP, Allen BA, Truta B, Sleisenger MH, Kim YS, (2004) BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 10: 191 - 195
12. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, Larue L, Pritchard C, Marais R, (2009) Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15: 294 - 303
13. Frame S, Cohen P, (2001) GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359: 1 - 16
14. Garnett MJ, Marais R, (2004) Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6: 313 - 319
15. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, et al, (2008) Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 40: 600 - 608
16. Hawkins NJ, Bariol C, Ward RL, (2002) The serrated neoplasia pathway. Pathology 34: 548 - 555
17. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA, (2003) Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63: 5198 - 5202
18. Ireland H, Kemp R, Houghton C, Howard L, Clarke AR, Sansom OJ, Winton DJ, (2004) Inducible Cre-mediated control of gene expression in the murine gastrointestinal tract: effect of loss of beta-catenin. Gastroenterology 126: 1236 - 1246
19. Jass JR, (2007a) Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50: 113 - 130
20. Jass JR, (2007b) Molecular heterogeneity of colorectal cancer: implications for cancer control. Surg Oncol 16: S7 - S9
21. Jass JR, Biden KG, Cummings MC, Simms LA, Walsh M, Schoch E, Meltzer SJ, Wright C, Searle J, Young J, et al, (1999) Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways. J Clin Pathol 52: 455 - 460
22. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, et al, (2004) B-RAF is a therapeutic target in melanoma. Oncogene 23: 6292 - 6298
23. Kemp R, Ireland H, Clayton E, Houghton C, Howard L, Winton DJ, (2004) Elimination of background recombination: somatic induction of Cre by combined transcriptional regulation and hormone binding affinity. Nucleic Acids Res 32: e92
24. MacDonald BT, Semenov MV, He X, (2007) SnapShot: Wnt/beta-catenin signaling. Cell 131: 1204
25. Makinen MJ, (2007) Colorectal serrated adenocarcinoma. Histopathology 50: 131 - 150
26. Mercer KE, Pritchard CA, (2003) Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653: 25 - 40
27. Mercer K, Giblett S, Green S, Lloyd D, DaRocha Dias S, Plumb M, Marais R, Pritchard C, (2005) Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res 65: 11493 - 11500
28. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS, (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436: 720 - 724
29. Minoo P, Jass JR, (2006) Senescence and serration: a new twist to an old tale. J Pathol 210: 137 - 140
30. Minoo P, Moyer MP, Jass JR, (2007) Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis. J Pathol 212: 124 - 133
31. Ng SS, Mahmoudi T, Danenberg E, Bejaoui I, de Lau W, Korswagen HC, Schutte M, Clevers H, (2009) Phosphatidylinositol 3-Kinase signaling does not activate the Wnt cascade. J Biol Chem 284: 35308 - 35313
32. Nosho K, Shima K, Irahara N, Kure S, Baba Y, Kirkner GJ, Chen L, Gokhale S, Hazra A, Spiegelman D, et al, (2009) DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. Clin Cancer Res 15: 3663 - 3671
33. O'Brien MJ, Yang S, Mack C, Xu H, Huang CS, Mulcahy E, Amorosino M, Farraye FA, (2006) Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am J Surg Pathol 30: 1491 - 1501
34. Old WM, Shabb JB, Houel S, Wang H, Couts KL, Yen CY, Litman ES, Croy CH, Meyer-Arendt K, Miranda JG, et al, (2009) Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell 34: 115 - 131
35. Orlow I, Begg CB, Cotignola J, Roy P, Hummer AJ, Clas BA, Mujumdar U, Canchola R, Armstrong BK, Kricker A, et al, (2007) CDKN2A germline mutations in individuals with cutaneous malignant melanoma. J Invest Dermatol 127: 1234 - 1243
36. Parfitt JR, Driman DK, (2007) Survivin and hedgehog protein expression in serrated colorectal polyps: an immunohistochemical study. Hum Pathol 38: 710 - 717
37. Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, Berghmans S, Mayhall EA, Traver D, Fletcher CD, et al, (2005) BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 15: 249 - 254
38. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, et al, (2003) High frequency of BRAF mutations in nevi. Nat Genet 33: 19 - 20
39. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE, (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418: 934
40. Sandmeier D, Benhattar J, Martin P, Bouzourene H, (2009) Serrated polyps of the large intestine: a molecular study comparing sessile serrated adenomas and hyperplastic polyps. Histopathology 55: 206 - 213
41. Sansom OJ, Reed KR, Hayes AJ, Ireland H, Brinkmann H, Newton IP, Batlle E, Simon-Assmann P, Clevers H, Nathke IS, et al, (2004) Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev 18: 1385 - 1390
42. Sansom OJ, Meniel V, Wilkins JA, Cole AM, Oien KA, Marsh V, Jamieson TJ, Guerra C, Ashton GH, Barbacid M, et al, (2006) Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc Natl Acad Sci USA 103: 14122 - 14127
43. Segditsas S, Tomlinson I, (2006) Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 25: 7531 - 7537
44. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA, (1996) Role of the INK4a locus in tumor suppression and cell mortality. Cell 85: 27 - 37
45. Soriano P, (1999) Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 21: 70 - 71
46. Tateyama H, Li W, Takahashi E, Miura Y, Sugiura H, Eimoto T, (2002) Apoptosis index and apoptosis-related antigen expression in serrated adenoma of the colorectum: the saw-toothed structure may be related to inhibition of apoptosis. Am J Surg Pathol 26: 249 - 256
47. van der Flier LG, Clevers H, (2009) Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol 71: 241 - 260
48. Wang L, Cunningham JM, Winters JL, Guenther JC, French AJ, Boardman LA, Burgart LJ, McDonnell SK, Schaid DJ, Thibodeau SN, (2003) BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 63: 5209 - 5212
49. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, et al, (2006) CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38: 787 - 793
50. Wellbrock C, Ogilvie L, Hedley D, Karasarides M, Martin J, Niculescu-Duvaz D, Springer CJ, Marais R, (2004) V599EB-RAF is an oncogene in melanocytes. Cancer Res 64: 2338 - 2342
51. Yang S, Farraye FA, Mack C, Posnik O, O'Brien MJ, (2004) BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am J Surg Pathol 28: 1452 - 1459